カルナバイオサイエンスの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2018/07/18 | 1,290 | 1,369 | 1,290 | 1,352 | +62 | +4.8% | 100,300 |
| 2018/07/17 | 1,304 | 1,312 | 1,280 | 1,290 | -22 | -1.7% | 42,400 |
| 2018/07/13 | 1,319 | 1,325 | 1,306 | 1,312 | -9 | -0.7% | 20,400 |
| 2018/07/12 | 1,319 | 1,346 | 1,315 | 1,321 | +2 | +0.2% | 25,600 |
| 2018/07/11 | 1,310 | 1,323 | 1,294 | 1,319 | -3 | -0.2% | 19,700 |
| 2018/07/10 | 1,350 | 1,351 | 1,305 | 1,322 | -3 | -0.2% | 64,800 |
| 2018/07/09 | 1,269 | 1,327 | 1,260 | 1,325 | +79 | +6.3% | 82,200 |
| 2018/07/06 | 1,215 | 1,258 | 1,201 | 1,246 | +60 | +5.1% | 75,500 |
| 2018/07/05 | 1,288 | 1,288 | 1,172 | 1,186 | -87 | -6.8% | 138,900 |
| 2018/07/04 | 1,296 | 1,309 | 1,260 | 1,273 | -22 | -1.7% | 66,800 |
| 2018/07/03 | 1,318 | 1,345 | 1,292 | 1,295 | -11 | -0.8% | 74,400 |
| 2018/07/02 | 1,335 | 1,337 | 1,303 | 1,306 | -13 | -1% | 41,600 |
| 2018/06/29 | 1,301 | 1,326 | 1,300 | 1,319 | +11 | +0.8% | 41,400 |
| 2018/06/28 | 1,290 | 1,330 | 1,288 | 1,308 | -30 | -2.2% | 97,500 |
| 2018/06/27 | 1,332 | 1,360 | 1,325 | 1,338 | -2 | -0.1% | 35,800 |
| 2018/06/26 | 1,337 | 1,350 | 1,328 | 1,340 | -2 | -0.1% | 39,500 |
| 2018/06/25 | 1,362 | 1,400 | 1,339 | 1,342 | -35 | -2.5% | 80,100 |
| 2018/06/22 | 1,378 | 1,382 | 1,361 | 1,377 | -34 | -2.4% | 55,300 |
| 2018/06/21 | 1,396 | 1,432 | 1,392 | 1,411 | +2 | +0.1% | 46,900 |
| 2018/06/20 | 1,376 | 1,411 | 1,337 | 1,409 | +8 | +0.6% | 112,800 |
| 2018/06/19 | 1,437 | 1,449 | 1,395 | 1,401 | -38 | -2.6% | 128,500 |
| 2018/06/18 | 1,485 | 1,496 | 1,417 | 1,439 | -61 | -4.1% | 88,900 |
| 2018/06/15 | 1,461 | 1,500 | 1,453 | 1,500 | +60 | +4.2% | 88,300 |
| 2018/06/14 | 1,510 | 1,525 | 1,440 | 1,440 | -99 | -6.4% | 130,100 |
| 2018/06/13 | 1,550 | 1,610 | 1,539 | 1,539 | -29 | -1.8% | 184,500 |
| 2018/06/12 | 1,549 | 1,610 | 1,532 | 1,568 | +9 | +0.6% | 192,600 |
| 2018/06/11 | 1,469 | 1,559 | 1,450 | 1,559 | +74 | +5% | 225,100 |
| 2018/06/08 | 1,427 | 1,493 | 1,421 | 1,485 | +74 | +5.2% | 204,200 |
| 2018/06/07 | 1,383 | 1,420 | 1,383 | 1,411 | +7 | +0.5% | 70,000 |
| 2018/06/06 | 1,362 | 1,412 | 1,361 | 1,404 | +52 | +3.8% | 139,600 |
| 2018/06/05 | 1,322 | 1,364 | 1,314 | 1,352 | +36 | +2.7% | 79,200 |
| 2018/06/04 | 1,313 | 1,327 | 1,304 | 1,316 | +7 | +0.5% | 34,500 |
| 2018/06/01 | 1,303 | 1,333 | 1,303 | 1,309 | -2 | -0.2% | 40,700 |
| 2018/05/31 | 1,317 | 1,329 | 1,306 | 1,311 | -6 | -0.5% | 28,100 |
| 2018/05/30 | 1,302 | 1,324 | 1,299 | 1,317 | -4 | -0.3% | 47,200 |
| 2018/05/29 | 1,343 | 1,357 | 1,320 | 1,321 | -34 | -2.5% | 64,400 |
| 2018/05/28 | 1,369 | 1,385 | 1,352 | 1,355 | -13 | -1% | 32,000 |
| 2018/05/25 | 1,393 | 1,410 | 1,365 | 1,368 | -25 | -1.8% | 41,000 |
| 2018/05/24 | 1,439 | 1,451 | 1,386 | 1,393 | -36 | -2.5% | 67,900 |
| 2018/05/23 | 1,423 | 1,452 | 1,413 | 1,429 | +6 | +0.4% | 80,900 |
| 2018/05/22 | 1,422 | 1,438 | 1,391 | 1,423 | +2 | +0.1% | 51,800 |
| 2018/05/21 | 1,361 | 1,424 | 1,360 | 1,421 | +57 | +4.2% | 90,600 |
| 2018/05/18 | 1,386 | 1,393 | 1,353 | 1,364 | -38 | -2.7% | 81,700 |
| 2018/05/17 | 1,350 | 1,418 | 1,346 | 1,402 | +65 | +4.9% | 193,500 |
| 2018/05/16 | 1,326 | 1,341 | 1,315 | 1,337 | +2 | +0.1% | 43,300 |
| 2018/05/15 | 1,332 | 1,352 | 1,324 | 1,335 | +15 | +1.1% | 36,600 |
| 2018/05/14 | 1,311 | 1,341 | 1,309 | 1,320 | -12 | -0.9% | 75,800 |
| 2018/05/11 | 1,343 | 1,349 | 1,317 | 1,332 | -15 | -1.1% | 68,200 |
| 2018/05/10 | 1,355 | 1,355 | 1,335 | 1,347 | +5 | +0.4% | 44,600 |
| 2018/05/09 | 1,356 | 1,363 | 1,337 | 1,342 | -10 | -0.7% | 62,300 |
1551～
1600
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「カルナバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| カルナバイオ | 31,000円 | -43.1% | - | 0.00% | - | 1.84倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
| ノイルイミューン | 17,300円 | -97.8% | - | 0.00% | - | 1.50倍 |
|
独自技術用いたＣＡＲ－Ｔ細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
| 日ケミファ | 151,100円 | +2.5% | - | 3.31% | 90.86倍 | 0.29倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
| ＶＩＳ | 89,000円 | +87.8% | +265.7% | 0.00% | 53.45倍 | 2.45倍 |
|
ｍＲＮＡ標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
| クリングル | 84,500円 | +240.0% | - | 0.00% | - | 2.75倍 |
|
細胞の増殖、保護、修復などの機能があるＨＧＦタンパク質を用いて、難治性疾患治療薬を開発 |
市場注目の銘柄
チャート関連のコラム
